MGNX
MGNX
NASDAQ · Biotechnology

Macrogenics Inc

$4.62
-0.24 (-4.94%)
As of Jun 30, 10:32 PM ET ·
Financial Highlights (FY 2026)
Revenue
149.50M
Net Income
-74,619,441
Gross Margin
75.9%
Profit Margin
-49.9%
Rev Growth
-0.5%
D/E Ratio
1.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 149.50M 150.30M 19.43M 16.17M
Gross Profit 113.49M 114.09M 6.80M 5.66M
Operating Income -72,838,416 -65,903,864 4.53M 3.44M
Net Income -74,619,441 -67,515,328 4.04M 2.70M
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Rev Growth -0.5% -0.5% +14.5% +17.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 82.55M 82.55M 6.65M 6.76M
Total Equity 65.56M 65.56M 36.37M 40.78M
D/E Ratio 1.26 1.26 0.18 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -65,670,160 -62,719,063 6.14M 4.71M
Free Cash Flow 2.37M 2.40M